KALARIS THERAPEUTICS INC (KLRS) Stock Price, Quote, News and Overview
NASDAQ:KLRS - Nasdaq - US4829291065 - Common Stock - Currency: USD
KLRS Quote, Performance and Key Statistics
NASDAQ:KLRS (6/6/2025, 8:03:36 PM)
3.3
+0.19 (+6.11%)
The current stock price of KLRS is 3.3 USD. In the past month the price decreased by -14.29%.
KLRS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.48 | 335.32B | ||
| AMGN | AMGEN INC | 13.99 | 156.11B | ||
| GILD | GILEAD SCIENCES INC | 14.53 | 139.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.13 | 53.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.23B | ||
| ARGX | ARGENX SE - ADR | 101.9 | 35.78B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.54 | 27.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| NTRA | NATERA INC | N/A | 22.36B | ||
| BIIB | BIOGEN INC | 8.42 | 19.51B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.29B |
Related stock screener links
About KLRS
Company Profile
Kalaris Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Palo Alto, California and currently employs 6 full-time employees. The company went IPO on 2020-07-30. Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Company Info
KALARIS THERAPEUTICS INC
628 Middlefield Road
Palo Alto CALIFORNIA US
Employees: 6
Phone: 16502492727
KALARIS THERAPEUTICS INC / KLRS FAQ
What is the stock price of KALARIS THERAPEUTICS INC today?
The current stock price of KLRS is 3.3 USD. The price increased by 6.11% in the last trading session.
What is the ticker symbol for KALARIS THERAPEUTICS INC stock?
The exchange symbol of KALARIS THERAPEUTICS INC is KLRS and it is listed on the Nasdaq exchange.
On which exchange is KLRS stock listed?
KLRS stock is listed on the Nasdaq exchange.
What is KALARIS THERAPEUTICS INC worth?
KALARIS THERAPEUTICS INC (KLRS) has a market capitalization of 61.71M USD. This makes KLRS a Micro Cap stock.
How many employees does KALARIS THERAPEUTICS INC have?
KALARIS THERAPEUTICS INC (KLRS) currently has 6 employees.
Should I buy KALARIS THERAPEUTICS INC (KLRS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KLRS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KLRS, evaluating the profitability, health, valuation and growth aspects
- KALARIS THERAPEUTICS INC (KLRS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KALARIS THERAPEUTICS INC (KLRS) Sales and EPS estimates to see what analysts future expectations are.
- KALARIS THERAPEUTICS INC (KLRS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KALARIS THERAPEUTICS INC (KLRS) Insider and Institutional Ownership to learn about the owners and their transactions.
- KALARIS THERAPEUTICS INC (KLRS) Stock Chart to make your own analysis
- KALARIS THERAPEUTICS INC (KLRS) Latest news and press-releases to stay up to date.
Does KALARIS THERAPEUTICS INC (KLRS) stock pay dividends?
KLRS does not pay a dividend.
When does KALARIS THERAPEUTICS INC (KLRS) report earnings?
KALARIS THERAPEUTICS INC (KLRS) will report earnings on 2025-08-07.
What is the Price/Earnings (PE) ratio of KALARIS THERAPEUTICS INC (KLRS)?
KALARIS THERAPEUTICS INC (KLRS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.13).
What is the Short Interest ratio of KALARIS THERAPEUTICS INC (KLRS) stock?
The outstanding short interest for KALARIS THERAPEUTICS INC (KLRS) is 0.44% of its float. Check the ownership tab for more information on the KLRS short interest.
KLRS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KLRS.
KLRS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KLRS. No worries on liquidiy or solvency for KLRS as it has an excellent financial health rating, but there are worries on the profitability.
KLRS Financial Highlights
Over the last trailing twelve months KLRS reported a non-GAAP Earnings per Share(EPS) of -6.13. The EPS decreased by -270.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.1% | ||
| ROE | -59.7% | ||
| Debt/Equity | 0 |
KLRS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to KLRS. The Buy consensus is the average rating of analysts ratings from 7 analysts.